-Reuters   The government has ordered a cut of nearly 20% in its 2014-15 healthcare budget due to fiscal strains, putting at risk key disease control initiatives in a country whose public spending on health is already among the lowest in the world. Two health ministry officials told Reuters on Tuesday that more than 60 billion rupees, or $948 million, has been slashed from their budget allocation of around $5 billion for the...

-The Indian Express The recent proposal by the National Commission for Women to legalise prostitution has opened up an old debate. It is a misnomer that legalisation would lead to improving the lives of women in prostitution by way of reduced harassment by the police and provision of healthcare facilities. Advocates of legalisation should first examine the experience of countries where prostitution has been legalised. The mere fact that licensing has...

-Business Standard India's mixed record on the Millennium Development Goals is a pointer to policy priorities In 2000, the United Nations held a Millennium Summit, at which the membership adopted the Millennium Development Goals (MDGs). Spanning a range of development indicators - poverty, gender, health, education and the environment - the MDGs essentially established a set of targets for the global community to achieve by 2015. The framework sets eight broad...

-The Hindu Business Line Questioning the kind of growth model pursued by the Government, civil society activists on Saturday called for a wider public debate on the reported move to curtail social sector spending on schemes such as the rural job guarantee scheme, MGNREGA, and for the HIV affected. "Considering the fact that the Government is forecasting a 5.3 per cent growth rate for this year, the social sector cuts in Budget...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...